Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma
对符合移植条件的初诊多发性骨髓瘤患者,比较达雷妥尤单抗、硼替佐米、来那度胺和地塞米松方案与硼替佐米、来那度胺和地塞米松方案的治疗成本(以应答者为单位)
期刊:
影响因子:
doi:10.18553/jmcp.2025.25142
Gautam, Santosh; Morrison, Laura; Thompson-Leduc, Philippe; Moore, Bronwyn; Wong, Gordon; Macomson, Brian; Khare, Vipin; Gupta-Werner, Niodita; Medhekar, Rohan